In this article, we will look at the 8 Healthcare Stocks Insiders Are Buying.
Insider buying tends to draw attention because insiders know their companies best. That is especially true in the healthcare sector, where company stock moves can be driven by regulatory headlines, clinical data, and shifting sentiment. In that kind of market, insider purchases tend to stand out because they can suggest that the management sees more value in the business than the market is currently giving it credit for.
The institutional case lines up with that view. J.P. Morgan Asset Management’s Undiscovered Managers Behavioral Value Fund says its behavioral value strategy looks for “significant insider buying” alongside “attractive fundamentals.” On the sector side, Franklin Templeton says healthcare offers an “attractive entry point,” supported by “positive earnings revisions” and “robust innovation in drug pipelines.” Capital Group makes a similar argument, pointing to a gap between “underlying business strength” and “appealing stock valuations.” Insider buying matters more when it appears in a part of the market that may already be undervalued on its own merits.
Against this backdrop, healthcare stocks seeing insider purchases deserve a closer look. We will now look at the 8 Healthcare Stocks Insiders Are Buying.
Our Methodology
We used the Finviz screener to identify healthcare stocks with a significant increase in insider ownership over the last six months. We then limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
8. Kodiak Sciences Inc. (NASDAQ:KOD)
On April 1, 2026, Kodiak Sciences Inc. (NASDAQ:KOD) reported Q4 EPS of ($1.05) compared to (84c) last year. Victor Perlroth, M.D., Chief Executive Officer, said momentum is building, citing “positive Phase 3 topline results” from the GLOW2 study and progress across late-stage and pipeline programs supporting the company’s long-term strategy.
On March 27, 2026, UBS raised its price target on Kodiak Sciences Inc. (NASDAQ:KOD) to $80 from $50 previously and maintained a Buy rating on the shares. UBS said it is bullish on both tarcocimab VEGF and IL6.
Similarly, H.C. Jefferies raised its price target on Kodiak Sciences Inc. (NASDAQ:KOD) to $56 from $39 previously and maintained a Buy rating on the shares, noting GLOW2 results showed improved safety and efficacy versus GLOW1, with the reformulation seen as a safety improvement and potential driver of durability in the Phase III DAYBREAK study, while also supporting earlier Biologics License Application timing.
Kodiak Sciences Inc. (NASDAQ:KOD) develops therapies for retinal diseases.
7. Wave Life Sciences Ltd. (NASDAQ:WVE)
On April 7, 2026, RBC Capital analyst Luca Issi lowered the price target on Wave Life Sciences Ltd. (NASDAQ:WVE) to $15 from $27 and maintained an Outperform rating as part of a Q1 biotech preview. Luca Issi said seasonal headwinds around gross-to-net, reimbursement resets, and fewer selling days may be exacerbated by weather impacts, particularly for launching and in-clinic products, while noting that a return of M&A activity and clarity on tariff and Most Favored Nation drug pricing could help offset broader macro pressures.
On March 27, 2026, BofA lowered its price target on Wave Life Sciences to $21 from $38 and maintained a Buy rating following updated Phase 1 data for WVE-007 in obesity. BofA said additional data is needed to support the monotherapy case, but noted potential opportunities in higher BMI patients and in combination or maintenance settings.
On March 26, 2026, Wave Life Sciences reported new Phase 1 INLIGHT trial data for WVE-007, showing that a single 240 mg dose led to reductions in visceral fat, waist circumference, and body weight, while preserving muscle, with up to 88% reduction in Activin E sustained for at least seven months. The treatment was generally safe and well-tolerated, with no serious adverse events, and additional cohorts showed similar trends, supporting plans to begin a Phase 2a multidose study in the second quarter of 2026 and further trials evaluating monotherapy and combination approaches.
Wave Life Sciences Ltd. (NASDAQ:WVE) develops RNA-based therapeutics.
